KYMR
$81.21
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Intraday
Recent News
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside
Kymera Therapeutics has begun first in human clinical trials of an IRF5 directed therapy, a new approach to targeting immune driven disease. The company has also advanced KT-621, its lead oral STAT6 degrader, with early data suggesting potential to rival or surpass a key existing therapy. These milestones highlight progress in Kymera Therapeutics' immunology pipeline at a time when interest in protein degradation platforms remains high. Kymera Therapeutics (NasdaqGM:KYMR) is drawing...
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic. That is not a minor pipeline update. Kymera Therapeutics missed on both revenue and earnings in Q4. Revenue ... Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans
Kymera Therapeutics has reported a higher quarterly and full-year loss for 2025, missing earnings and revenue expectations while also filing a US$500 million at-the-market follow-on equity offering and a US$392.14 million shelf registration tied to employee stock plans. Alongside these financing moves, Kymera appointed experienced drug developer Dr. Neil Graham as Chief Development Officer, underscoring its commitment to advancing its emerging oral immunology pipeline despite widening...